Par Pharmaceutical, Inc. is a U.S.-based generic drug manufacturer and marketer headquartered in Woodcliff Lake, New Jersey. The company develops, manufactures, and distributes a wide range of generic pharmaceuticals, including tablets, capsules, liquids, and injectable products.
Par is known for its focus on complex generics and authorized generics, often entering into licensing and settlement agreements with brand-name pharmaceutical companies to launch products ahead of patent expiry.
Also known as Par.
Jury awarded USD 884,943,990 in single damages in AMITIZA antitrust trial; wholesaler/retailer sums subject to trebling. Will appeal, assess provision and revise FY2025 filings; minimal FY2026 impact.
